| Hazard Information | Back Directory | [Uses]
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis[1][2]. | [in vivo]
Tralokinumab (3 mg/kg; intraperitoneal injection; once every other day; from day 35 to day 63) can inhibit pulmonary fibrosis and reduce epithelial cell apoptosis in a humanized SCID mouse model of pulmonary fibrosis[2]. | Animal Model: | Female C.B-17-scid-beige (C.B-17SCID/bg) mice received single-cell preparations of IPF and normal fibroblasts via tail vein injection[2] | | Dosage: | 3 mg/kg | | Administration: | Intraperitoneal injection; once every other day; from day 35 to day 63 | | Result: | Blocked aberrant lung remodeling, promoted lung repair and restored epithelial integrity.
Significantly decreased fibrotic alterations.
Reduced serum CC16 (a marker of epithelial injury) and reduced BAL caspase 3 activity.
Enhanced the expression of epithelial-associated genes, including E-cadherin and all of the surfactants.
|
| [IC 50]
IL-13 | [References]
[1] A Wollenberg, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437-449. DOI:10.1111/bjd.19574
[2] Murray LA, et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol. 2014 May;50(5):985-94. DOI:10.1165/rcmb.2013-0342OC |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|